Quality of Life Assessment in Antidepressant Treatment of Patients with Depression and/Or Anxiety Disorder

Abstract

Introduction: Chronic HCV infection is chronic inflamatory liver disease caused by hepatitis C virus. Anti HCV prevalence among intravenous drug users (IVDU) is very high and it accounts 40% -90% (60%-90%) with the risk of 80% of developing the chronic infection. Aim: The aims of this study were: a) to compare clinical characteristics of chronic HCV infection among IVDU and non-users population and to detect their impact to treatment outcome; b) to investigate the treatment efficacy comparing sustained viral response (SVR) in these two populations in Tuzla Canton. Patients and methods: The study was retrospective-prospective and included 45 IVDU of both sexes from Tuzla Canton which were treated from chronic HCV infection with Pegilated interferon 2a/2b + ribavirin in the Clinic for Infectious Diseases and Clinic for Internal Disease of University Clinical Centre in Tuzla. The control group were presented by non-users who completed therapy in both Clinics. For statistical analyses it was used statistical package SPSS 20,0 (SPSS Inc, Chicago, IL, USA) with tests of descriptive statistics with measures of central tendency and dispersion. Quantitative variables were tested by t-test or by Mann-Whitney test. Qualitative variables were tested by hi-square test or by Fisher’s test. The standard analyse of level’s risk was used too. The analyse of predictive value of EVR for achieving the ETR and SVR was done by cross-tabulation. The impact of known factors for achieving the SVR was evaluated by logistic regression analyses. All tests were done with statistical level of significance of 95% (p=0,05). Results: Men were more dominant in the test group (93,3% / 61,7%), also younger age (p<0,001) and lower BMI (p=0,019). The test group had significant higher basal values of Le, Hb, Plt and ALT and tendency to lower stages of fibrosis (p=0,08). The difference in genotype frequencies was statistically significant (p=0,001) with clearly dominance of G3 and G4 among IVDU. Treatment was not complited by two patients in both groups (4,4% /3,3%). EVR was significantly higher in test group (p=0,001) so did the ETR (p=0,002) and SVR (p<0,001). Predictive factors for SVR were: age (negative predictive factor), male sex, absence of reduction of pegilated interferon and ribavirin, Metavir stage of fibrosis and presence of EVR. Conclusion: Population of IVDU were adherent to treatment protocol and with excellent treatment response they justified the hope of health care workers for success treatment of this population.

The Economic Impact of Depression Treatment in India

“…Berndt et al 1998, Fletcher 2013, Schwebel and Brezausek 2008, Bayer et al 2019, Cobb-Clark et al 2020. Pharmacotherapy is associated with improvements in life satisfaction, cognition, and decision-making among people with depression (Dzevlan et al 2019, Prado et al 2018. Quasi-experimental studies find an effect of mental health on labor market outcomes (Biasi et al 2020), or suggest that mental health may mediate the economic impacts of external shocks (Baranov et al 2015, Hanaoka et al 2018).…”

Uso de antidepressivos e percepção de saúde entre adultos de 40 anos ou mais: estudo longitudinal.

“…Melhoras dos sintomas depressivos com moderadas mudanças positivas na percepção da qualidade de vida têm sido relacionadas ao uso de AD para os pacientes que respondem ao tratamento [4,15,16,32,33], principalmente quando o uso de AD está associado à Terapia Cognitiva Comportamental (TCC) [4] . Para àqueles que não respondem ao tratamento, há, além da piora dos sintomas depressivos, frustação com o tratamento e prescritor, comprometimento das relações sociais (familiares e trabalho), maior risco de mortalidade e piora na percepção sobre a vida [17,18,34].…”

“…O efeito dos AD na qualidade de vida percebida por seus usuários ainda continua controverso, apontando tanto melhora na qualidade de vida [4,15,16] quanto resultados negativos sobre a sua percepção entre os usuários de AD [17,18]. Avaliações sobre desfechos relacionados à qualidade de vida tem ficado em segundo plano nos ensaios clínicos para depressão e os estudos existentes carecem de metodologias mais consistentes [4,[17][18][19], o que tem dificultado o entendimento do papel dos AD na qualidade de vida dos pacientes.…”